Loading...

SLRX SALARIUS PHARMACEUTICALS INC Company Mergers 8-K Filing

SLRS

SLRX

SALARIUS PHARMACEUTICALS INC

(SLRX)

2025 8-K

Summary

Summary

Merger Bonus Approved

Compliance Regained

Compliance Update

Merger Agreement Update

Nasdaq Compliance Regained

Compliance Update

Stock Offering Update

Filing Amendment

Management Change

Stock Split Announced

Equity Offerings

Merger of Equals

Loan Defaults (Secured, Uns...

Merger of Equals

Equity Standard Compliance

Compliance Issues

Merger of Equals

Voluntary Delisting

Financial Update

Merger Agreement

Annual Meeting Results

Securities Agreement

Annual Meeting Notice

Stockholder Equity

Clinical Trial Closure

Clinical Trial Hold

Clinical Data Announcement

Reverse Stock Split

Departure of CEO and Change...

Financial Results

Annual Meeting Approval

Securities Purchase Agreement

Patent Issuance

External Links:

Salarius Pharmaceuticals approved a $225,000 bonus for acting CEO Mark J. Rosenblum contingent on the merger completion with Decoy Therapeutics, which began on January 10, 2025. This filing reports on the board's decision made on October 21, 2025, regarding the merger bonuses.

AI Assistant

SALARIUS PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.